Europe
Absci Corporation inked a deal with Merck. Absci will leverage its Bionic Protein non-standard amino acid technology and AI-integrated Drug Creation Platform to create enzymes for Merck.
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
On Friday morning, AstraZeneca’s rare disease group Alexion and Switzerland-based Neurimmune entered into a collaboration and licensing agreement for NI006.
He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
What the appearance of yet another variant shows is the “unpredictability of the emergence of SARS-CoV-2 variants,” according to the researchers who discovered IHU.
Researchers are finding new insights every day about diseases like diabetes that are well understood. For example, new science found another way the body regulates blood sugar levels than just insulin. For that and more research news, continue reading.
The acquisition is expected to bolster Odyssey’s drug development capabilities in immunology and oncology.
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
PRESS RELEASES